What is the 13F Pro Quality Score for SERA?

13F Pro ranks SERA PROGNOSTICS, INC. (SERA) on the 13F Pro Quality Score, a 0–100 composite of 32 fundamental signals including return on invested capital, free cash flow consistency, balance-sheet strength, earnings quality, growth durability, and valuation discipline. The score refreshes after each 10-K and 10-Q filing on SEC EDGAR. View SERA's current score at https://13fpro.ai/research/SERA (free sign-up required for the full ranking).

Which hedge funds own the most SERA stock?

Based on the most recent Form 13F-HR filings on SEC EDGAR, the largest reported institutional holders of SERA include BAKER BROS. ADVISORS, Whetstone Capital Advisors,, abrdn plc. Holdings are reported quarterly within 45 days of quarter-end and updated on https://13fpro.ai/research/SERA as soon as new 13F filings post.

Where does 13F Pro source SERA data?

All SERA PROGNOSTICS, INC. fundamentals and ownership data come directly from SEC EDGAR. SERA PROGNOSTICS, INC. files with the SEC under CIK 1534969. 13F Pro ingests XBRL financial facts from 10-K and 10-Q filings, Form 13F-HR institutional holdings, and Form 4 insider transactions, with no third-party rewrites or estimates.

What sector is SERA in?

SERA PROGNOSTICS, INC. (SERA) is classified in the Healthcare sector. 13F Pro publishes sector-level fund flow analysis and quality leaders at https://13fpro.ai/research/sector/healthcare.

How often is SERA research updated on 13F Pro?

SERA's fundamentals refresh within hours of each new 10-K or 10-Q filing on SEC EDGAR. Institutional ownership updates after each quarterly 13F filing window. Insider transactions update after each Form 4 filing. The 13F Pro Quality Score recalculates after every fundamentals refresh.

SERA PROGNOSTICS, INC.(SERA)Stock Analysis

AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →

Healthcare →Nasdaq

Institutional-grade research for retail investors

SEC EDGAR: CIK 1534969 SERA stock profile & AI dashboard →

13F Pro Quality Score

7.9/100

Rank #2,829 of 2,879 stocks

View Healthcare peers →

Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Aug 14, 2026.

Revenue Growth

2.1/100

Profitability

0.3/100

Balance Sheet

7.0/100

Earnings Quality

30.0/100

Free Cash Flow

0.1/100

Institutional Flow

96.5/100

Revenue Scale

0.2/100

Dilution Risk

0.2/100

SERA Stock Analysis & AI Quality Score

AI stock analysis and institutional research for SERA PROGNOSTICS, INC. (SERA), a Healthcare sector company. 13F Pro's AI-powered ranking engine scores SERA at 7.9/100 on a 32-signal composite quality model, placing it at rank #2,829 of 2,879 stocks — the bottom half of the AI-ranked universe. SERA scores in the top quartile across institutional flow (96.5). Areas of concern include free cash flow (0.1) and revenue scale (0.2), which score below median versus the broader universe. Shareholder dilution risk is elevated at 0.2/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q1 2026), SERA PROGNOSTICS, INC. reports quarterly revenue of $14.0K, net income of $-8.4M, free cash flow of $-8.8M. Top institutional holders of SERA by reported 13-F value include BAKER BROS. ADVISORS, Whetstone Capital Advisors,, abrdn plc, based on the most recent SEC filings. SERA trades on the Nasdaq exchange and files with the SEC under CIK 1534969. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate SERA daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for SERA PROGNOSTICS, INC. directly from SEC EDGAR. SERA PROGNOSTICS, INC.'s 13F Pro composite quality score has ranged between 5 and 29 since 2022, currently 7.9 — a declining long-term trajectory across 16 quarterly and live scoring snapshots.

Revenue

Q1 2026

$14.0K

Net Income

Q1 2026

$-8.4M

Free Cash Flow

Q1 2026

$-8.8M

Revenue & Net Income

Earnings Per Share

Key Financials Over Time

Export Financial Table · Pro+

Revenue

-69.8% YoY

$81.0KFY 2025

FY22 $268.0KFY25 $81.0K

Net Income

+27.7% YoY

$-31.9MFY 2025

FY22 $-44.2MFY25 $-31.9M

Operating Income

+20.0% YoY

$-36.5MFY 2025

FY22 $-45.7MFY25 $-36.5M

EPS (Diluted)

+53.1% YoY

$-0.67FY 2025

FY22 $-1.43FY25 $-0.67

Total Assets

-12.4% YoY

$101.9MFY 2025

FY22 $116.3MFY25 $101.9M

Op. Cash Flow

+26.0% YoY

$-25.6MFY 2025

FY22 $-34.6MFY25 $-25.6M

Metric	FY 2025	FY 2022
Revenue	$81.0K -69.8%	$268.0K
Net Income	$-31.9M +27.7%	$-44.2M
Operating Income	$-36.5M +20.0%	$-45.7M
EPS (Diluted)	$-0.67 +53.1%	$-1.43
Total Assets	$101.9M -12.4%	$116.3M
Operating Cash Flow	$-25.6M +26.0%	$-34.6M

AI Insight: SERA Financial Trends

Pre-revenue SERA burns ~$6–9M operating cash per quarter with equity eroding steadily toward $68M — runway is the only metric that matters.

• Revenue has been $0M across all eight quarters from Q2 2024 through Q1 2026 — no commercialization progress visible in financials.

• Equity fell from $95M in Q1 2025 to $68M in Q1 2026, a $27M decline in four quarters driven entirely by operating losses.

• Operating cash outflow spiked to -$9M in Q1 2026, the worst quarter in the dataset, after holding at -$5M to -$7M prior.

⚠ At the Q1 2026 burn rate of -$9M/quarter, remaining equity of $68M implies roughly 7–8 quarters before capital is exhausted.

⚠ No debt appears on the balance sheet; any debt raise to extend runway would introduce leverage risk not yet present.

⚠ A Q1 2025 equity jump from $48M to $95M signals a capital raise — monitor for any similar dilutive financing in coming quarters.

AI Insight: SERA Ratio Trends

SERA's return metrics remain deeply negative across all periods, though a meaningful improvement from Q4 2024 trough levels offers a tentative floor.

• ROE deteriorated from -55.6% in Q2 2024 to a trough of -71.8% in Q4 2024, before recovering to -34.5% in Q1 2025.

• ROIC followed the same arc: -64.9% in Q3 2024, bottoming at -78.8% in Q4 2024, then improving to -39.0% in Q1 2025.

• Since Q1 2025, ROE has re-deteriorated from -34.5% to -49.7% in Q1 2026, reversing the post-trough recovery.

⚠ ROIC at -55.4% in Q1 2026 is approaching the Q4 2024 trough of -78.8% — renewed deterioration trend warrants close monitoring.

⚠ OpMargin, NPM, and D/E are entirely absent across all periods, severely limiting visibility into operational performance and leverage.

Get alerted when SERA's score changes

Free account: watchlist tracking, the daily AI brief, and the AI screener.

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Available Research

13F Pro tracks comprehensive data for SERA PROGNOSTICS, INC. including:

SEC EDGAR filings (10-K, 10-Q, 8-K)

XBRL financial facts (revenue, EPS, margins)

Insider transactions (Form 4)

Institutional 13F holdings

Quality rankings (32 signals)

AI analyst debates & daily meetings

Historical financial trends

Peer comparison & sector analysis

Top Institutional Holders of SERA

BAKER BROS. ADVISORS LP
$11.2M5,498,170 sh
Whetstone Capital Advisors, LLC
$6.7M3,306,889 sh
abrdn plc
$5.2M2,550,775 sh
PSP Research LLC
$4.9M2,396,685 sh
Vivo Capital, LLC
$3.4M1,650,440 sh
VANGUARD CAPITAL MANAGEMENT LLC
$2.4M1,204,115 sh
CAPTRUST FINANCIAL ADVISORS
$1.1M536,761 sh
GEODE CAPITAL MANAGEMENT, LLC
$738.5K363,617 sh
SANDERS MORRIS HARRIS LLC
$639.3K314,950 sh
CITADEL ADVISORS LLC
$505.3K248,909 sh

Fund	Value	Shares
BAKER BROS. ADVISORS LP	$11.2M	5,498,170
Whetstone Capital Advisors, LLC	$6.7M	3,306,889
abrdn plc	$5.2M	2,550,775
PSP Research LLC	$4.9M	2,396,685
Vivo Capital, LLC	$3.4M	1,650,440
VANGUARD CAPITAL MANAGEMENT LLC	$2.4M	1,204,115
CAPTRUST FINANCIAL ADVISORS	$1.1M	536,761
GEODE CAPITAL MANAGEMENT, LLC	$738.5K	363,617
SANDERS MORRIS HARRIS LLC	$639.3K	314,950
CITADEL ADVISORS LLC	$505.3K	248,909

More Healthcare Companies

View all Healthcare →

AAPG

ASCENTAGE PHARMA GROUP INTERNATIONAL

AARD

Aardvark Therapeutics, Inc.

ABBV

AbbVie Inc.

ABCL

AbCellera Biologics Inc.

ABEO

ABEONA THERAPEUTICS INC.

ABOS

Acumen Pharmaceuticals, Inc.

ABPWW

Abpro Holdings, Inc.

ABSI

Absci Corp

Put SERA on your watchlist

Track score changes the day SERA PROGNOSTICS, INC. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.

View Pricing

Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Popular Research

AAPL

Apple

MSFT

Microsoft

NVDA

NVIDIA

GOOG

Alphabet

AMZN

Amazon

Is SERA a good stock to buy?

13F Pro's AI-powered analysis of SERA PROGNOSTICS, INC. (SERA) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for SERA are available on the SERA stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing.

Which hedge funds own SERA?

Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling SERA. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of SERA PROGNOSTICS, INC.'s investment landscape.